Printed from Voxsanity (voxsanity.com.au) — NCT07674615 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 1 Ovarian Cancer Trial, Not Yet Recruiting
NCT07674615
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 80 years old.
- People who have been diagnosed through a tissue biopsy with advanced or returning high-grade cancer of the ovaries, fallopian tubes, or peritoneum (the lining of the abdomen).
- People whose cancer has come back or gotten worse after at least one prior chemotherapy treatment containing platinum, where the cancer progressed less than 6 months after the last platinum treatment.
- People whose cancer has come back or gotten worse after at least three prior platinum-based chemotherapy treatments, where the cancer progressed 6 months or more after the last platinum treatment, and who are not able to receive standard platinum-based chemotherapy.
- People with advanced ovarian cancer that has spread through the bloodstream, who are not able to receive standard treatment, and whose life expectancy with current treatment is estimated to be more than 3 months but roughly not more than 12 months.
- People whose cancer can be measured on scans according to a standard set of measurement rules (called RECIST 1.1), or whose cancer recurrence or progression has been confirmed using another standard method (called GCIG criteria).
- People whose BRCA gene status and HRD (a measure of DNA repair ability in tumour cells) status are already known.
- People who have tumour tissue available (either stored or freshly collected) that can be tested for a protein called TROP-2.
- People whose tumour tissue shows a TROP-2 H-score above 200 (a measure of how much of the TROP-2 protein is present).
- People with a general health and activity level rated 0, 1, or 2 on a standard scale used by doctors (called the ECOG scale), meaning they are able to carry out at least some daily activities.
- People whose bone marrow, blood, and organ function are healthy enough to allow them to receive treatment.
- People who have had at least a 2-week break since their last treatment (including chemotherapy, immunotherapy, radiotherapy, or certain other medicines) or major surgery.
- People who have had at least a 2-week break since taking high-dose steroid medicines (note: low-dose steroids below the equivalent of 20 mg of prednisone per day are permitted).
- People who have recovered from side effects of previous treatments to a mild level or better before joining.
- People who have read and signed a consent form agreeing to take part in the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously been treated with a type of chemotherapy called a topoisomerase I inhibitor.
- People who have a known allergy or sensitivity to the study drug, its breakdown products, or its ingredients.
- People who need to take, or have previously taken, certain medications that are not permitted in this trial (for example, drugs known as UGT1A1 inhibitors).
- People who have a condition called Gilbert's syndrome (a genetic liver condition affecting how the body processes certain substances).
- People who have, or have had within the past 5 years, another cancer that is currently not controlled or whose treatment would interfere with this trial or affect its results (note: certain early-stage cancers and breast cancer without active disease or signs of return may not apply — confirm with trial site).
- People who have had a serious episode of bleeding, bowel blockage, or a hole in the bowel or digestive tract within the 6 months before starting the trial, and whose life expectancy is estimated to be less than 3 months.
- People who have had a significant heart condition in the past 6 months, such as uncontrolled high blood pressure, unstable chest pain (angina), severe heart failure, or a serious irregular heartbeat requiring medication (except stable atrial fibrillation).
- People with a known, clinically significant active lung condition such as COPD or other moderate-to-severe ongoing breathing problems within the past 6 months.
- People with known active cancer that has spread to the brain or the lining around the brain and spinal cord (carcinomatous meningitis), unless their brain metastases have been treated and the cancer in the brain has been stable for at least 4 weeks, all neurological symptoms have returned to their usual baseline, there is no sign of new or growing brain tumours, and they are taking no more than the equivalent of 20 mg of prednisone per day — people with carcinomatous meningitis are excluded regardless of stability.
- People with a history of uncontrolled seizures or active neurological disorders.
- People known to have HIV with a detectable viral load, or who are taking medications that may interfere with how the study drug is processed in the body.
- People with active hepatitis B (HBV) or hepatitis C (HCV) infection, or a history of either with a currently detectable viral load.
- People with a known tendency to bleed or an active bleeding disorder.
- People experiencing moderate or severe loss of appetite, nausea, or vomiting (Grade 2 or higher), or signs of a bowel blockage.
- People with other ongoing medical or mental health conditions that, in the opinion of the treating doctor, could affect the trial results or prevent the person from completing the study.
- People with other unstable medical problems, including serious heart issues, active treatment for a blood clot in the lungs (pulmonary embolism), recent stroke, kidney or liver insufficiency, or an active serious infection requiring intravenous antibiotics.
- People with any medical condition that, in the opinion of the treating doctor, would make participation in this trial unsafe.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 86-21-64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Shanghai Gynecologic Oncology Group
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
30 June 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Objective response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.